OBJECTIVE: To investigate the significance of treatment with antithyroid drugs longer than 12 months on lasting remission in Graves' hyperthyroid patients, and to study clinical and laboratory parameters of prognostic value. PATIENTS: Fifty-two untreated Graves' hyperthyroid patients were assigned at random to two therapeutic groups. They were treated with carbimazole during 12 and 24 months in Group I (n = 28) and Group II (n = 24), respectively. MEASUREMENTS: Serum levels of FT4, T3, sTSH and TSH receptor antibody (TRAb) were measured before starting treatment and at regular intervals during treatment and follow-up after drug withdrawal. We compared the relapse rate in both groups of patients, at short (2-yr) and long-term (5-yr) periods after drug withdrawal. Also, we compared clinical and biochemical parameters between patients who stayed in remission and who had relapse. RESULTS: At the end of the short-term period, relapse had occurred in 13 (46.4%) Group I patients and in 13 (54.1%) Group II patients, p = 0.36. At the end of the long-term period, relapse had occurred in 24 (85.7%) Group I and 20 (83.3%) Group II patients, p = 0.78. No difference could be observed between patients who had stayed in remission and who had suffered relapse, within the 5-yr follow-up period regarding to goiter size, frequency of ophthalmopathy, TSH and TRAb levels. CONCLUSIONS: The high relapse rate observed could be due to high iodine intake in our country. In this study and in a review of the available data, we have been unable to find any rational basis for courses of antithyroid drugs longer than twelve months for the treatment of Graves' hyperthyroidism.(ABSTRACT TRUNCATED AT 250 WORDS)
RCT Entities:
OBJECTIVE: To investigate the significance of treatment with antithyroid drugs longer than 12 months on lasting remission in Graves' hyperthyroidpatients, and to study clinical and laboratory parameters of prognostic value. PATIENTS: Fifty-two untreated Graves' hyperthyroidpatients were assigned at random to two therapeutic groups. They were treated with carbimazole during 12 and 24 months in Group I (n = 28) and Group II (n = 24), respectively. MEASUREMENTS: Serum levels of FT4, T3, sTSH and TSH receptor antibody (TRAb) were measured before starting treatment and at regular intervals during treatment and follow-up after drug withdrawal. We compared the relapse rate in both groups of patients, at short (2-yr) and long-term (5-yr) periods after drug withdrawal. Also, we compared clinical and biochemical parameters between patients who stayed in remission and who had relapse. RESULTS: At the end of the short-term period, relapse had occurred in 13 (46.4%) Group I patients and in 13 (54.1%) Group II patients, p = 0.36. At the end of the long-term period, relapse had occurred in 24 (85.7%) Group I and 20 (83.3%) Group II patients, p = 0.78. No difference could be observed between patients who had stayed in remission and who had suffered relapse, within the 5-yr follow-up period regarding to goiter size, frequency of ophthalmopathy, TSH and TRAb levels. CONCLUSIONS: The high relapse rate observed could be due to high iodine intake in our country. In this study and in a review of the available data, we have been unable to find any rational basis for courses of antithyroid drugs longer than twelve months for the treatment of Graves' hyperthyroidism.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors: A Pinchera; P Liberti; E Martino; G F Fenzi; L Grasso; L Rovis; L Baschieri; G Doria Journal: J Clin Endocrinol Metab Date: 1969-02 Impact factor: 5.958
Authors: A M Madec; M C Laurent; Y Lorcy; A M Le Guerrier; A Rostagnat-Stefanutti; J Orgiazzi; H Allannic Journal: Clin Endocrinol (Oxf) Date: 1984-09 Impact factor: 3.478
Authors: J H Romaldini; N Bromberg; R S Werner; L M Tanaka; H F Rodrigues; M C Werner; C S Farah; L C Reis Journal: J Clin Endocrinol Metab Date: 1983-09 Impact factor: 5.958
Authors: A P Weetman; S Ratanachaiyavong; G W Middleton; W Love; R John; G M Owen; C Darke; J H Lazarus; R Hall; A M McGregor Journal: Q J Med Date: 1986-04
Authors: H Tamai; T Nakagawa; O Fukino; N Ohsako; R Shinzato; H Suematsu; K Kuma; F Matsuzuka; S Nagataki Journal: Ann Intern Med Date: 1980-04 Impact factor: 25.391
Authors: Suyeon Park; Eyun Song; Hye-Seon Oh; Mijin Kim; Min Ji Jeon; Won Gu Kim; Tae Yong Kim; Young Kee Shong; Doo Man Kim; Won Bae Kim Journal: Endocrine Date: 2019-06-24 Impact factor: 3.633
Authors: E Mazza; M Carlini; D Flecchia; A Blatto; O Zuccarini; S Gamba; S Beninati; M Messina Journal: J Endocrinol Invest Date: 2008-10 Impact factor: 4.256